AIM Stock Overview
An immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 3 more risks
AIM ImmunoTech Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.23 |
| 52 Week High | US$0.62 |
| 52 Week Low | US$0.16 |
| Beta | -0.36 |
| 11 Month Change | -15.76% |
| 3 Month Change | -36.62% |
| 1 Year Change | -48.86% |
| 33 Year Change | -84.69% |
| 5 Year Change | -53.06% |
| Change since IPO | -99.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| AIM | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 23.0% | 4.0% | 2.0% |
| 1Y | -48.9% | 18.0% | 32.4% |
Return vs Industry: AIM underperformed the US Biotechs industry which returned 18.3% over the past year.
Return vs Market: AIM underperformed the US Market which returned 32.6% over the past year.
Price Volatility
| AIM volatility | |
|---|---|
| AIM Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: AIM's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: AIM's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1966 | 27 | Thomas Equels | aimimmuno.com |
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions.
AIM ImmunoTech Inc. Fundamentals Summary
| AIM fundamental statistics | |
|---|---|
| Market cap | US$13.57m |
| Earnings (TTM) | -US$23.93m |
| Revenue (TTM) | US$190.00k |
75.4x
P/S Ratio-0.6x
P/E RatioIs AIM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AIM income statement (TTM) | |
|---|---|
| Revenue | US$190.00k |
| Cost of Revenue | US$36.00k |
| Gross Profit | US$154.00k |
| Other Expenses | US$24.08m |
| Earnings | -US$23.93m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 81.05% |
| Net Profit Margin | -12,594.21% |
| Debt/Equity Ratio | 93.8% |
How did AIM perform over the long term?
See historical performance and comparison